BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
July 27, 2021 09:00 ET
|
BioStem Technologies, Inc.
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing...
Rapid Therapeutic Prepares to file Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA
June 02, 2021 07:00 ET
|
Rapid Therapeutic Science Laboratories
DALLAS, June 02, 2021 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of...
Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
March 17, 2021 08:33 ET
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR
February 23, 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
ROSEN, A LEADING AND RANKED FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
February 10, 2021 16:28 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
December 28, 2020 08:00 ET
|
CNS Pharmaceuticals, Inc.
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
December 21, 2020 07:00 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
November 12, 2020 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07, 2020 08:30 ET
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
September 15, 2020 08:07 ET
|
Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....